RecruitingNot ApplicableNCT06434480

SBRT in HCC With Oligoprogression on First-line Immunotherapy

Stereotactic Body Radiotherapy (SBRT) in Advanced Hepatocellular Carcinoma With Oligoprogression on First-line Immunotherapy

Sponsor

Chinese University of Hong Kong

Enrollment

30 participants

Start Date

Jun 21, 2024

Study Type

INTERVENTIONAL

Conditions

HCC

Summary

HCC is a huge healthcare burden in Hong Kong and is one of the top 5 cancers in terms of incidence and mortality in Hong Kong. Patients with advanced HCC are treated with immunotherapy-based as first-line treatment as a standard of care. At the moment, there is limited evidence to guide subsequent treatments after patients progressed on immunotherapy. Oligoprogression is a term used to describe patients who had limited progression (usually less than 3 sites) on systemic therapy, with the rest of the lesions controlled. Previous studies in non-HCCs have shown that addition of locoregional treatment (e.g. radiotherapy) may prolong the use of systemic therapy, resulting in improved survival, but this has been relatively unexplored for HCC. In this prospective, single-arm study, we aim to evaluate the treatment outcome, efficacy and safety of the addition of radiotherapy to oligoprogressive sites for patients who had limited progression on First-line Immunotherapy.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether targeted radiation (called SBRT — stereotactic body radiation therapy) can control the limited number of growing tumor spots in people with liver cancer (hepatocellular carcinoma, or HCC) who are receiving immunotherapy as first-line treatment but experiencing limited tumor progression. **You may be eligible if...** - You are 18 or older with a confirmed HCC diagnosis - You are currently receiving approved first-line immunotherapy (such as atezolizumab plus bevacizumab, durvalumab, or nivolumab-based combinations) - You have "oligoprogression" — meaning 5 or fewer tumors are growing while the rest are controlled - The growing tumor(s) can be safely targeted with SBRT - Your general health score is 0 or 1 (ECOG) - Your liver function meets the study requirements **You may NOT be eligible if...** - You have more than 5 total growing lesions - You have significant liver disease, prior liver transplant, or liver function that cannot safely tolerate radiation - You are pregnant Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

RADIATIONStereotactic Body Radiation Therapy (SBRT)

* For intrahepatic progression: 27.5-50Gy in 5 fractions over 2 weeks will be given. * For extrahepatic progression: an aim to give ablative dose will be given.